Expand your value story with real-world evidence and regulatory expertise
To continually make a case for the merits of your product, turn to the power of real-world evidence (RWE), regulatory insights, and therapeutically aligned medical writing. We design and execute post-approval studies that bolster your value story, delivering data that satisfies payers and regulators while building trust with patients and their health care providers.
Amplify your product’s impact with lifecycle management
We support your post-launch product with holistic regulatory, compliance, market access, and communications consulting. We begin by generating real-world data to demonstrate value — but we also communicate that value to stakeholders, protect value through compliance, and weigh value against risk to assess marketing authorization renewals. Let our integrated team help your drug get the most out of its lifecycle.
Our solution experts
Sangeeta Budhia
Senior Vice President, Pricing & Market Access
Jackie Vanderpuye-Orgle, Ph.D.
Senior Vice President, and Global Head of Advanced Analytics, RWE & HEOR
Mike D’Ambrosio
Senior Vice President and Global Head, Real World Research
Sanjay Vyas
President, Safety & Logistics and Country Head of India
Katie Connelly
Senior Vice President, Global Head of Regulatory Affairs
Our solution experts
Sangeeta Budhia
Senior Vice President, Pricing & Market Access
Jackie Vanderpuye-Orgle, Ph.D.
Senior Vice President, and Global Head of Advanced Analytics, RWE & HEOR
Mike D’Ambrosio
Senior Vice President and Global Head, Real World Research
Sanjay Vyas
President, Safety & Logistics and Country Head of India
Katie Connelly
Senior Vice President, Global Head of Regulatory Affairs
Services
Real-world evidence and market access strategy
Regulators and payors look to unmet needs and product value as determinants for access. By focusing on these outcomes, value demonstration in the later stages of development is designed to clearly convey how the drug will benefit patients.
Our RWE and late phase access teams partner with you to demonstrate value pre, during, and post launch. Our insights ensure that the clinical data you’ve invested years in developing translates to optimal access, ROI, and most importantly improved patient outcomes.
21%more likely drug launch with RWD
Our research with the Economist Intelligence revealed how real-world data (RWD) strategies like ours significantly improve the likelihood of a drug launching.
Regulatory compliance
The speed and finesse with which you handle a consent decree, compliance audit, data integrity issue, and authority relations and communications can mean everything to a successful launch. Our compliance team, unequaled in experience and perspective (with former regulators on staff), can get you to safe harbor with reduced down-time, preserved ROI, and authority trust intact.
Our solutions include risk evaluation and mitigation; compliance services; PSUR and DSUR services; integrity safety; GCP, GLP, and GMP consulting; data integrity services; health authority consulting and liaison; compliance audits; inspection training; and more.
1,300+regulatory specialists, including former regulators from agencies across the world
Our compliance consulting group is equipped with the expertise to help you mitigate risk, manage remediations, and restore brand and regulatory confidence.
Lifecycle optimization
With the rising cost of developing new treatments and mounting challenges in development overall, it’s Business 101 to explore the full spectrum of lifecycle management options that maximize the ROI of existing assets. Our expert regulatory and market access teams are ready to provide competitive assessments and positioning to keep your products relevant, as well as handle maintenance submissions, APRs, DMFs, DSURs, PSURs, RIMs, regulatory intelligence requirements, and more — getting it right the first time.
1,350+annual product reviews
We’re ready to evaluate your treatments with an annual product review (APR), to ensure your treatments continually reach their full potential.
Medical communications
Engage the people who matter most. At Parexel, we combine a comprehensive portfolio of medical communications services with expertise in all major therapeutic areas, as well as clinical development, patient engagement, real-world evidence, health economics, market access, regulatory, and more — to communicate vital data to your stakeholders.
Our team consists of Medical Affairs strategists who collaborate with highly skilled PhD, PharmD, and MD writers, seasoned medical editors, meeting logistics experts, and creative, digital, and design specialists. Together, we enhance educational experiences and bring your science to life across every stage of development.
Our writers have deep experience across therapeutic areas, resulting in more relevant, impactful medical communications.
Integrated evidence generation planning
Parexel offers expertise in developing and delivering IEGP for various organizations, from big pharma to small biotech. Our services include early-stage strategy development, tactical planning, function-specific support, and advisory services.
By partnering with us for integrated evidence planning, you can maximize your assets' potential, streamline development processes, and improve commercial outcomes in a competitive market.
Operational excellence
Constantly evolving how we deliver trials
The purpose of our Operational Excellence and Delivery Office is to continuously and consistently improve the way we run your trials. By assembling our most experienced, cross-functional team members, we create best practices business wide that accelerate timelines, generate compelling evidence, promote innovation — and empower us to deliver With Heart™.
Frost & Sullivan's 2023 North American Customer Value Leadership Award
Parexel Recognized with Frost & Sullivan's 2023 North American Customer Value Leadership Award for impactful real-world evidence solutions addressing customer needs.
Related insights
Blog
Regulatory outsourcing: Applying change management best practices for smoother transitions
Jul 24, 2025
Blog
Maximizing value: The critical role of health-related quality of life data collection in pivotal trials
Jul 21, 2025
Article
Regulation pathway/strategy: Key considerations for foreign medical product registration in China
Jul 1, 2025
Blog
RNA-based therapies: Aligning CMC strategies with “borrowed” FDA regulatory guidance
Jun 30, 2025
Blog
FDA’s new priority voucher review program: Potential implications and next steps for sponsors
Jun 20, 2025
Blog
Traceability, proportionality, and flexibility: Strategies for operationalizing ICH E6(R3)
Jun 17, 2025
Blog
Manufacturing and control strategies for Cell and Gene Therapy products: Navigating EU and US regulatory requirements
Jun 12, 2025
Blog
Optimize your CMC strategy: Five steps to avoid regulatory setbacks
May 15, 2025
Blog
Integrated evidence planning and RWE: Realizing value throughout the development lifecycle
May 13, 2025
Webinar
Regulatory roadmap for biotechs: Effective strategies for streamlined early phase development
May 6, 2025
Blog
FDA guidances for development of oligonucleotide therapeutics: Key takeaways for sponsors
May 5, 2025
Blog
Advancing the transition from animal models to alternative methods: FDA's initiative and sponsors' opportunities
May 1, 2025
Whitepaper
How real-world data is powering rare disease research Part 2. RWD advances in Europe
Apr 18, 2025
Whitepaper
How real-world data is powering rare disease research Part 3. RWD advances in China
Apr 18, 2025
Whitepaper
How real-world data is powering rare disease research Part 1. RWD advances in North America
Apr 18, 2025
Whitepaper
Biosimilar development: Optimizing PK/PD studies
Mar 28, 2025
Webinar
Navigating Clinical Trials in Japan: From Regulatory Strategy to Operational Success
Mar 28, 2025
Blog
Challenges and best practices for developing Antibody-Drug Conjugates (ADCs)
Mar 17, 2025
Blog
Streamlining orally inhaled product (OIP) development with EMA’s new guideline – the clinical perspective
Mar 17, 2025
Blog
Accelerated approval: Navigating FDA’s recent guidance and confirmatory trial considerations
Mar 6, 2025
Related insights
Blog
Regulatory outsourcing: Applying change management best practices for smoother transitions
Jul 24, 2025
Blog
Maximizing value: The critical role of health-related quality of life data collection in pivotal trials
Jul 21, 2025
Article
Regulation pathway/strategy: Key considerations for foreign medical product registration in China
Jul 1, 2025
Blog
RNA-based therapies: Aligning CMC strategies with “borrowed” FDA regulatory guidance
Jun 30, 2025
Blog
FDA’s new priority voucher review program: Potential implications and next steps for sponsors
Jun 20, 2025
Blog
Traceability, proportionality, and flexibility: Strategies for operationalizing ICH E6(R3)
Jun 17, 2025
Blog
Manufacturing and control strategies for Cell and Gene Therapy products: Navigating EU and US regulatory requirements
Jun 12, 2025
Blog
Optimize your CMC strategy: Five steps to avoid regulatory setbacks
May 15, 2025
Blog
Integrated evidence planning and RWE: Realizing value throughout the development lifecycle
May 13, 2025
Webinar
Regulatory roadmap for biotechs: Effective strategies for streamlined early phase development
May 6, 2025
Blog
FDA guidances for development of oligonucleotide therapeutics: Key takeaways for sponsors
May 5, 2025
Blog
Advancing the transition from animal models to alternative methods: FDA's initiative and sponsors' opportunities
May 1, 2025
Whitepaper
How real-world data is powering rare disease research Part 2. RWD advances in Europe
Apr 18, 2025
Whitepaper
How real-world data is powering rare disease research Part 3. RWD advances in China
Apr 18, 2025
Whitepaper
How real-world data is powering rare disease research Part 1. RWD advances in North America
Apr 18, 2025
Whitepaper
Biosimilar development: Optimizing PK/PD studies
Mar 28, 2025
Webinar
Navigating Clinical Trials in Japan: From Regulatory Strategy to Operational Success
Mar 28, 2025
Blog
Challenges and best practices for developing Antibody-Drug Conjugates (ADCs)
Mar 17, 2025
Blog
Streamlining orally inhaled product (OIP) development with EMA’s new guideline – the clinical perspective
Mar 17, 2025
Blog
Accelerated approval: Navigating FDA’s recent guidance and confirmatory trial considerations
Mar 6, 2025